PPC
PRCT icon

Park Place Capital’s Procept Biorobotics PRCT Stock Holding History

Park Place Capital’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$813 Buy
36
+9
+33% +$225 ﹤0.01% 1067
2026
Q1 		$675 Buy
+27
New +$761 ﹤0.01% 829
2025
Q4 		– Sell
-8
Closed -$286 – 831
2025
Q3 		$286 Hold
8
– – ﹤0.01% 781
2025
Q2 		$453 Hold
8
– – ﹤0.01% 797
2025
Q1 		$466 Hold
8
– – ﹤0.01% 813
2024
Q4 		$644 Buy
+8
New +$683 ﹤0.01% 795

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Park Place Capital's PRCT Position: Q2 2026 in Review

Park Place Capital increased its Procept Biorobotics (PRCT) stake by 33% in Q2 2026, buying an estimated $225 and bringing the position to 36 shares worth $813. The position accounts for ﹤0.01% of the portfolio, ranked #1067.

Park Place Capital first reported a position in PRCT in Q4 2024 and has held it in 6 quarters since. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Park Place Capital held 36 shares of Procept Biorobotics worth $813 as of Q2 2026.
  • Park Place Capital bought 9 Procept Biorobotics shares in Q2 2026, an estimated $225.
  • Procept Biorobotics made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #1067 holding.
  • Park Place Capital first reported a position in Procept Biorobotics in Q4 2024 and has held it in 6 quarters since.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.